MedTrace Logo

Daily Tadalafil in Diabetic ED Patients

NCT06962462 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-05-08

No results posted yet for this study

Summary

This study evaluates the effect of 5 mg daily tadalafil therapy on serum levels of Endothelin-1 and E-selectin in diabetic male patients with erectile dysfunction. Outcomes will be compared pre- and post-treatment versus healthy controls.

Conditions

  • Erectile Dysfunction Associated With Type 2 Diabetes Mellitus

Interventions

DRUG

Methyl Cellulose Placebo

Oral administration of inert methyl cellulose placebo tablets once daily for 3 months. Used as a comparator in healthy control participants to evaluate changes in Endothelin-1 and E-selectin serum levels.

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Abdelmawgoud, M.Sc · Faculty of Medicine, South Valley University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2025-08-05
Completion
2025-08-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06962462 on ClinicalTrials.gov